Search Result

Results for "

Cancer Gene Therapy

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) DNA/RNA Synthesis (2) Liposome (2) Photosensitizer (1) YAP (1)
By Research Areas:	Cancer (4)
Oligonucleotides:	Cap Analogs (2) Cholesterol (1)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Oligonucleotides

Targets Recommended: BCRP CGRP Receptor LAG-3 Dan family MALT1 NEKs

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-145973A

3'OMe-m7GpppAmpG (ammonium) solution (100mM) m7(3'OMeG)(5')ppp(5')(2'OMeA)pG ammonium solution (100mM)	DNA/RNA Synthesis	Others
3'OMe-m7GpppAmpG ammonium solution (100mM) is a trinucleotide Cap analogue. 3'OMe-m7GpppAmpG ammonium shows a significant translational efficiency. 3'OMe-m7GpppAmpG ammonium can be used as a potential molecular biology tool in the field of mRNA vaccines and mRNA transfection, such as protein production, gene therapy and anti-cancer immunization .

HY-149664

3β-[N-(N′,N′-Dimethylaminoethyl)carbamoyl]cholesterol DC-Chol	Liposome	Cancer
3β-[N-(N′,N′-Dimethylaminoethyl)carbamoyl]cholesterol, a lipid, has been investigated in cancer gene therapy and vaccine delivery system .

HY-173139

TEAD-IN-19	YAP	Cancer
TEAD-IN-19 (Compound 1l) is a transcriptional inhibitor of TEAD, exhibiting inhibition rates of 38.5%, 36.2%, 57.8%, and 71.3% against TEAD1, TEAD2, TEAD3, and TEAD4, respectively, at a concentration of 10 μM. TEAD-IN-19 shows potent anti-proliferative and anti-migratory activities in prostate cancer cell lines and significantly reduces the expression of TEAD-regulated downstream genes. TEAD-IN-19 holds promise for research in the field of cancer therapy .

HY-170490

TTQ-SA	Photosensitizer Apoptosis	Cancer
TTQ-SA is a near-infrared (NIR) spiro-AIEgen (aggregation-induced emission luminogen), that converts near-infrared light (NIR) into thermal energy, causing thermal damage and death of tumor cells. TTQ-SA exhibits cellular uptake and targeting ability in cancer cell MF-7. TTQ-SA silences the expression of survivin gene with combination of DNAzyme, enhances the sensitivity of tumor cells to photothermal therapy .

HY-145973

3'OMe-m7GpppAmpG m7(3'OMeG)(5')ppp(5')(2'OMeA)pG	DNA/RNA Synthesis	Others
3'OMe-m7GpppAmpG is a trinucleotide Cap analogue. 3'OMe-m7GpppAmpG shows a significant translational efficiency. 3'OMe-m7GpppAmpG can be used as a potential molecular biology tool in the field of mRNA vaccines and mRNA transfection, such as protein production, gene therapy and anti-cancer immunization .

HY-169478

Lipid N2-3L	Liposome	Cancer
Lipid N2-3L is an ionizable cationic lipid (pK_a = 8.99) that can be used to generate supramolecular lipid nanoparticles (SMLNPs) for mRNA delivery. Lipid nanoparticles formed by encapsulating a luciferase reporter gene with Lipid N2-3L were detected to accumulate in the lymph nodes of mice, indicating that they can effectively enter the mouse immune system. Lipid nanoparticles formed by encapsulating ovalbumin mRNA and the TLR7/8 agonist Resiquimod (HY-13740) with Lipid N2-3L were able to reduce tumor volume and increase survival in the MC-38-OVA mouse colon cancer model. Lipid N2-3L can be used in the research of drug delivery for cancer-related therapies .

Cat. No.	Product Name

HY-L077

Anti-Pancreatic Cancer Compound Library	3,250 compounds
Pancreatic cancer is a devastating disease with a low overall survival rate. Chemotherapy is the most common treatment for patients presenting with advanced pancreatic cancer. More recently, the era of targeted therapies has generated a lot of interest in discovering better approaches for patients with pancreatic cancer. Commonly mutated genes in pancreatic cancer include K-ras (in 74-100% of cases), p16INK4a (up to 98%), p53 (43 to 76%), DPC4 (about 50%), HER-2/neu (in about 65%) and FHIT (found in 70% of cases). Other genes involved are notch1, Akt-2, BRCA2 and COX-2. These proteins are important targets of target therapies for pancreatic cancer. MCE offers a unique collection of 3,250 compounds with identified and potential anti- pancreatic cancer activity. These compounds target K-Ras, p53, HER2, Notch, AKT, etc. MCE anti-pancreatic cancer compound library is a useful tool for anti-pancreatic cancer drugs screening and other related research.

Anti-Pancreatic Cancer Compound Library

3,250 compounds

Pancreatic cancer is a devastating disease with a low overall survival rate. Chemotherapy is the most common treatment for patients presenting with advanced pancreatic cancer. More recently, the era of targeted therapies has generated a lot of interest in discovering better approaches for patients with pancreatic cancer. Commonly mutated genes in pancreatic cancer include K-ras (in 74-100% of cases), p16INK4a (up to 98%), p53 (43 to 76%), DPC4 (about 50%), HER-2/neu (in about 65%) and FHIT (found in 70% of cases). Other genes involved are notch1, Akt-2, BRCA2 and COX-2. These proteins are important targets of target therapies for pancreatic cancer.

MCE offers a unique collection of 3,250 compounds with identified and potential anti- pancreatic cancer activity. These compounds target K-Ras, p53, HER2, Notch, AKT, etc. MCE anti-pancreatic cancer compound library is a useful tool for anti-pancreatic cancer drugs screening and other related research.

HY-L015

PI3K/Akt/mTOR Compound Library	738 compounds
The PI3K/Akt/mTOR pathway controls many cellular processes that are important for the formation and progression of cancer, including apoptosis, transcription, translation, metabolism, angiogenesis, and cell cycle progression. Every major node of this signaling network is activated in a wide range of human tumors. Mechanisms for the pathway activation include activation of receptor tyrosine kinases (RTKs) upstream of PI3K, mutation or amplification of PIK3CA encoding p110α catalytic subunit of PI3K, mutation or loss of PTEN tumor suppressor gene, and mutation or amplification of Akt1. Once the pathway is activated, signaling through Akt can stimulate a series of substrates including mTOR which is involved in protein synthesis. Thus, inhibition of this pathway is an attractive concept for cancer prevention and/or therapy. Currently some mTOR inhibitors are approved for several indications, and there are several novel PI3K/Akt/mTOR inhibitors in clinical trials. MCE owns a unique collection of 738 compounds that can be used for PI3K/Akt/mTOR pathway research. PI3K/Akt/mTOR Compound Library also acts as a useful tool for anti-cancer drug discovery.

PI3K/Akt/mTOR Compound Library

738 compounds

The PI3K/Akt/mTOR pathway controls many cellular processes that are important for the formation and progression of cancer, including apoptosis, transcription, translation, metabolism, angiogenesis, and cell cycle progression. Every major node of this signaling network is activated in a wide range of human tumors. Mechanisms for the pathway activation include activation of receptor tyrosine kinases (RTKs) upstream of PI3K, mutation or amplification of PIK3CA encoding p110α catalytic subunit of PI3K, mutation or loss of PTEN tumor suppressor gene, and mutation or amplification of Akt1. Once the pathway is activated, signaling through Akt can stimulate a series of substrates including mTOR which is involved in protein synthesis. Thus, inhibition of this pathway is an attractive concept for cancer prevention and/or therapy. Currently some mTOR inhibitors are approved for several indications, and there are several novel PI3K/Akt/mTOR inhibitors in clinical trials.

MCE owns a unique collection of 738 compounds that can be used for PI3K/Akt/mTOR pathway research. PI3K/Akt/mTOR Compound Library also acts as a useful tool for anti-cancer drug discovery.

Cat. No.	Product Name	Type

HY-145973A

3'OMe-m7GpppAmpG (ammonium) solution (100mM) m7(3'OMeG)(5')ppp(5')(2'OMeA)pG ammonium solution (100mM)	Gene Sequencing and Synthesis
3'OMe-m7GpppAmpG ammonium solution (100mM) is a trinucleotide Cap analogue. 3'OMe-m7GpppAmpG ammonium shows a significant translational efficiency. 3'OMe-m7GpppAmpG ammonium can be used as a potential molecular biology tool in the field of mRNA vaccines and mRNA transfection, such as protein production, gene therapy and anti-cancer immunization .

HY-149664

3β-[N-(N′,N′-Dimethylaminoethyl)carbamoyl]cholesterol DC-Chol	Drug Delivery
3β-[N-(N′,N′-Dimethylaminoethyl)carbamoyl]cholesterol, a lipid, has been investigated in cancer gene therapy and vaccine delivery system .

Cat. No.	Product Name		Classification

HY-145973A

3'OMe-m7GpppAmpG (ammonium) solution (100mM) m7(3'OMeG)(5')ppp(5')(2'OMeA)pG ammonium solution (100mM)		Cap Analogs
3'OMe-m7GpppAmpG ammonium solution (100mM) is a trinucleotide Cap analogue. 3'OMe-m7GpppAmpG ammonium shows a significant translational efficiency. 3'OMe-m7GpppAmpG ammonium can be used as a potential molecular biology tool in the field of mRNA vaccines and mRNA transfection, such as protein production, gene therapy and anti-cancer immunization .

HY-149664

3β-[N-(N′,N′-Dimethylaminoethyl)carbamoyl]cholesterol DC-Chol		Cholesterol
3β-[N-(N′,N′-Dimethylaminoethyl)carbamoyl]cholesterol, a lipid, has been investigated in cancer gene therapy and vaccine delivery system .

HY-145973

3'OMe-m7GpppAmpG m7(3'OMeG)(5')ppp(5')(2'OMeA)pG		Cap Analogs
3'OMe-m7GpppAmpG is a trinucleotide Cap analogue. 3'OMe-m7GpppAmpG shows a significant translational efficiency. 3'OMe-m7GpppAmpG can be used as a potential molecular biology tool in the field of mRNA vaccines and mRNA transfection, such as protein production, gene therapy and anti-cancer immunization .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.